Generated by All in One SEO v5.0.1.1, this is an llms.txt file, used by LLMs to index the site.

# Avigen

Accelerating Immunotherapy Development

## Sitemaps

- [XML Sitemap](https://avigen.bio/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [Avigen and Etcembly Complete Collaboration Evaluating AI-Designed Multi-specific Cell Engagers](https://avigen.bio/etcembly/) - London, UK – 12 March 2026 – Avigen Ltd (“the Company”), a privately held Contract Research Organisation developing advanced preclinical immunotherapy R&D services using its proprietary microfluidic platform and Etcembly Ltd, a techbio company leveraging generative AI for the development of novel biologics, today announced the successful completion of a collaborative study focused on the
- [Avigen Strengthens Growth Trajectory Through Royal Academy of Engineering Enterprise Fellowship Award](https://avigen.bio/avigen-strengthens-growth-trajectory-through-royal-academy-of-engineering-enterprise-fellowship-award/) - London, UK – 1 January 2026 – Avigen Ltd (“the Company”), a privately held Contract Research Organisation developing advanced preclinical immunotherapy R&D services using its proprietary microfluidic platform, today announced that Neelima KC, Founder of Avigen Ltd. has been awarded a prestigious Royal Academy of Engineering Enterprise Fellowship. Delivered through the Royal Academy of Engineering’s
- [Avigen Raises £300k from SFC Capital to Launch CRO Services](https://avigen.bio/seed-funding/) - Avigen Raises £300k from SFC Capital to Launch Immunotherapy CRO Services London, UK – 31 March 2025 – Avigen (“the Company”), a privately held Contract Research Organisation spun out from Imperial College London developing advanced preclinical immunotherapy R&D services using its proprietary microfluidic platform, today announced the successful close of a £300,000 seed funding round
- [Avigen Selected to Participate in the DeepTech Catalyst Biotech Incubator Programme](https://avigen.bio/deep-tech-catalyst/) - Avigen Awarded £300K Grant to Accelerate Cell Therapy R&D Innovation London, UK – 11 February 2026 – Avigen Ltd (“the Company”), a privately held Contract Research Organisation developing advanced preclinical immunotherapy R&D services using its proprietary microfluidic platform, today announced its participation in the DeepTech Catalyst Biotech Incubator (DTC Bio) programme, formerly known as the
- [Avigen enters Collaboration with NK:IO to Advance NK Cell Therapies for Solid Tumours](https://avigen.bio/nkio-collaboration/) - London, UK – 12 September 2025 – Avigen Ltd (“the Company”), a privately held Contract Research Organisation developing advanced preclinical immunotherapy R&D services using its proprietary microfluidic platform, today announced a preclinical research and development (R&D) collaboration with NK:IO, a biotechnology company pioneering natural killer (NK) cell-based therapies for haematological and solid tumours. This collaboration
- [Avigen Joins the White City Incubator](https://avigen.bio/white-city-incubator/) - Avigen Joins the White City Incubator We are excited to announce that Avigen has moved into the White City Incubator, marking an exciting new chapter for our company as we continue to develop and scale our platform and associated service offerings. Located in the heart of the White City Innovation District, this world-class facility provides
- [Avigen Awarded £300K Grant to Accelerate Cell Therapy R&D Innovation](https://avigen.bio/icure/) - Avigen Awarded £300K Grant to Accelerate Cell Therapy R&D Innovation London, UK – 1 April 2025 – Avigen (“the Company”), a privately held Contract Research Organisation spun out from Imperial College London developing advanced preclinical immunotherapy R&D services using its proprietary microfluidic platform, today announced that it has been awarded a £300,000 Innovate UK Innovation-to-Commercialisation

## Pages

- [Home](https://avigen.bio/) - Avigen provides analytical immunotherapy and cell therapy R&D services using avidity to identify potent and safe lead drug candidates faster.
- [About us](https://avigen.bio/about/) - aboutAvigen is a Contract Research Organisation, spun out from Imperial College London. At Avigen, we are developing the next generation of preclinical research and development services for immunotherapies, using our proprietary microfluidic platform. By assessing cellular avidity at high-throughput, we rapidly identify, sort, and isolate the most therapeutically valuable, target-specific cells from a broad pool
- [Technology](https://avigen.bio/technology/) - A new dimension in immune cell selection Our platform is capable of assessing cellular avidity, the total binding strength between immune and target cells, to precisely identify and select the most potent immunotherapy candidates.By uniting robust characterisation with high-throughput sorting and isolation of viable cells, the platform accelerates lead discovery and streamlines R&D workflows. Scientists
- [Contact us](https://avigen.bio/contact/) - get in touchWant to work with us? Get in touch, we would love to hear from you. Interested in working together or collaborating? We partner with biotech and pharma focused on immunotherapies for solid tumours. Our Location 58 Wood Lane, Scale Space,W12 7RZ, London, UK Email info@avigen.bio Social media LinkedIn Please enable JavaScript in your
- [Service page](https://avigen.bio/service-page/) - We accelerate and de-risk your preclinical development We measure what truly matters - cellular avidity - helping you uncover the next blockbuster therapies in your pipeline, faster and with confidence. Learn more Learn more We accelerate and de-risk your preclinical development We measure what truly matters - cellular avidity - helping you uncover the next
- [Case studies](https://avigen.bio/case-studies-page/) - CARCAR-iNKTSolid tumourAvidity-based CAR-iNKT target engagement and in-vivo efficacy prediction​ Solid tumourT cellsTCR T CellsAvidity-based detection, sorting and isolation of TCR T cells AntibodiesCell engagerSolid tumourT cellsAssessment of cell engager-mediated T cell target engagement and function ADCCNK cellsSolid tumourAvidity assessment of cetuximab-mediated NK cell target engagement and function
- [Samples](https://avigen.bio/samples-intake/) - Please enable JavaScript in your browser to complete this form.Please enable JavaScript in your browser to complete this form.Your DetailsName *FirstLastCompany or Institution *Email Address *🧬 Effector Cell Information01Cell IdentitySample Name / IDPassage NumberSourceNumber of VialsCells per VialHas this cell been engineered?YesNoTherapeutic Target(s)Complete if cell has been engineeredEngineering Method— Select —Lentiviral VectorRetroviral VectorElectroporation / mRNACRISPR/Cas9Transposon
- [Brochure](https://avigen.bio/brochure/) - Download our service brochure Please enable JavaScript in your browser to complete this form.Please enable JavaScript in your browser to complete this form.Name *FirstLastEmail *Organisation *Job Title *- Select -Academic ResearcherBusiness DevelopmentIndustry Research ScientistInnovation or Partnership LeadLab Technican or StaffOtherIndustry *- Select -AcademiaBiotechnologyCRO / CDMO / CRDMOPharmaceuticalOtherPlease specify *Please specify *Subscribe to newsletterI would like
- [Company and Science news](https://avigen.bio/news/) - March 12, 2026Avigen and Etcembly Complete Collaboration Evaluating AI-Designed Multi-specific Cell EngagersPress ReleaseLearn more February 11, 2026Avigen Selected to Participate in the DeepTech Catalyst Biotech Incubator ProgrammePress ReleaseLearn more January 12, 2026Avigen Strengthens Growth Trajectory Through Royal Academy of Engineering Enterprise Fellowship AwardPress ReleaseLearn more September 12, 2025Avigen enters Collaboration with NK:IO to Advance NK
- [test](https://avigen.bio/test/)
- [Partnering and Collaborations](https://avigen.bio/partnering/) - Partnerships are at our core Partnerships and collaborations are integral to Avigen’s mission of accelerating the development of immunotherapies and biologics to cure cancer. We form mutually beneficial relationships with global industry partners and academic institutions to enhance our capabilities and unlock the full potential of cellular therapies. Call for pilot study partners Avigen is actively

## Projects

- [VoxAI: Empowering Communication with AI Voice Generation](https://avigen.bio/projects/voxai-empowering-communication-with-ai-voice-generation/) - Integrating neural network models into existing systems or software applications, enabling businesses to leverage AI capabilities seamlessly. In today's fast-paced and data-driven world, businesses are constantly seeking innovative ways to gain a competitive edge, make smarter decisions, and deliver exceptional customer experiences. Pacific hake false trevally queen parrotfish black Prickleback moss revally queen parrotfish black
- [Speechify: Your Personal AI Voice Generator Companion](https://avigen.bio/projects/speechify-your-personal-ai-voice-generator-companion/) - Integrating neural network models into existing systems or software applications, enabling businesses to leverage AI capabilities seamlessly. In today's fast-paced and data-driven world, businesses are constantly seeking innovative ways to gain a competitive edge, make smarter decisions, and deliver exceptional customer experiences. Pacific hake false trevally queen parrotfish black Prickleback moss revally queen parrotfish black
- [Voicemate: Customizable AI Voice for Every Message](https://avigen.bio/projects/voicemate-customizable-ai-voice-for-every-message/) - Integrating neural network models into existing systems or software applications, enabling businesses to leverage AI capabilities seamlessly. In today's fast-paced and data-driven world, businesses are constantly seeking innovative ways to gain a competitive edge, make smarter decisions, and deliver exceptional customer experiences. Pacific hake false trevally queen parrotfish black Prickleback moss revally queen parrotfish black
- [HealthCareAI: Personalized diagnostics and treatment recommendations with Neural Networks](https://avigen.bio/projects/healthcareai-personalized-diagnostics-and-treatment-recommendations-with-neural-networks/) - Integrating neural network models into existing systems or software applications, enabling businesses to leverage AI capabilities seamlessly. In today's fast-paced and data-driven world, businesses are constantly seeking innovative ways to gain a competitive edge, make smarter decisions, and deliver exceptional customer experiences. Pacific hake false trevally queen parrotfish black Prickleback moss revally queen parrotfish black
- [AutoDrive: Autonomous vehicle navigation with advanced Neural Networks](https://avigen.bio/projects/autodrive-autonomous-vehicle-navigation-with-advanced-neural-networks/) - Integrating neural network models into existing systems or software applications, enabling businesses to leverage AI capabilities seamlessly. In today's fast-paced and data-driven world, businesses are constantly seeking innovative ways to gain a competitive edge, make smarter decisions, and deliver exceptional customer experiences. Pacific hake false trevally queen parrotfish black Prickleback moss revally queen parrotfish black
- [Smart Assist](https://avigen.bio/projects/smart-assist-2/) - Integrating neural network models into existing systems or software applications, enabling businesses to leverage AI capabilities seamlessly. In today's fast-paced and data-driven world, businesses are constantly seeking innovative ways to gain a competitive edge, make smarter decisions, and deliver exceptional customer experiences. Pacific hake false trevally queen parrotfish black Prickleback moss revally queen parrotfish black
- [Smart Assist](https://avigen.bio/projects/smart-assist/) - Integrating neural network models into existing systems or software applications, enabling businesses to leverage AI capabilities seamlessly. In today's fast-paced and data-driven world, businesses are constantly seeking innovative ways to gain a competitive edge, make smarter decisions, and deliver exceptional customer experiences. Pacific hake false trevally queen parrotfish black Prickleback moss revally queen parrotfish black
- [Smart HomeX](https://avigen.bio/projects/smart-homex/) - Integrating neural network models into existing systems or software applications, enabling businesses to leverage AI capabilities seamlessly. In today's fast-paced and data-driven world, businesses are constantly seeking innovative ways to gain a competitive edge, make smarter decisions, and deliver exceptional customer experiences. Pacific hake false trevally queen parrotfish black Prickleback moss revally queen parrotfish black
- [Secure Shield](https://avigen.bio/projects/secure-shield/) - Integrating neural network models into existing systems or software applications, enabling businesses to leverage AI capabilities seamlessly. In today's fast-paced and data-driven world, businesses are constantly seeking innovative ways to gain a competitive edge, make smarter decisions, and deliver exceptional customer experiences. Pacific hake false trevally queen parrotfish black Prickleback moss revally queen parrotfish black
- [Health CareIQ](https://avigen.bio/projects/health-careiq/) - Integrating neural network models into existing systems or software applications, enabling businesses to leverage AI capabilities seamlessly. In today's fast-paced and data-driven world, businesses are constantly seeking innovative ways to gain a competitive edge, make smarter decisions, and deliver exceptional customer experiences. Pacific hake false trevally queen parrotfish black Prickleback moss revally queen parrotfish black
- [DeepVision: Enhancing image recognition with Neural Networks](https://avigen.bio/projects/deepvision-enhancing-image-recognition-with-neural-networks-2/) - Neural networks are a fundamental component of Artificial Intelligence (AI) systems Integrating neural network models into existing systems or software applications, enabling businesses to leverage AI capabilities seamlessly. In today's fast-paced and data-driven world, businesses are constantly seeking innovative ways to gain a competitive edge, make smarter decisions, and deliver exceptional customer experiences. Pacific hake
- [DeepVision: Enhancing image recognition with Neural Networks](https://avigen.bio/projects/deepvision-enhancing-image-recognition-with-neural-networks/) - Neural networks are a fundamental component of Artificial Intelligence (AI) systems Integrating neural network models into existing systems or software applications, enabling businesses to leverage AI capabilities seamlessly. In today's fast-paced and data-driven world, businesses are constantly seeking innovative ways to gain a competitive edge, make smarter decisions, and deliver exceptional customer experiences. Pacific hake

## Team Members

- [Dr Andrew Fadden](https://avigen.bio/team/andrew-fadden/)
- [Dr Neelima KC](https://avigen.bio/team/neelima-kc/)
- [Dr Sam Au](https://avigen.bio/team/dr-sam-au/)
- [Tobias Gamper](https://avigen.bio/team/tobias-gamper/)

## Careers

- [Temporary Laboratory Technician](https://avigen.bio/careers/lab-technician/) - Temporary role (July–December 2025) supporting lab-based R&D of contract research services.

## Services

- [Immunotherapy discovery](https://avigen.bio/services/discovery/) - AI image generators can synthesize new, unique images from scratch and providing best silutions.
- [Immunotherapy validation](https://avigen.bio/services/validation/) - AI image generators can synthesize new, unique images from scratch and providing best silutions.

## Case Studies

- [Avidity-based CAR-iNKT target engagement and in-vivo efficacy prediction​](https://avigen.bio/case-study-archive/car-inkt/) - Discover how avidity-driven functional profiling enables accurate prediction of CAR-iNKT therapy performance before animal studies. Using a dynamic, physiologically relevant platform, CAR-iNKT constructs were quantitatively ranked based on tumour engagement strength, with avidity profiles directly correlating with in vivo tumour control and survival outcomes. High-avidity cell fractions demonstrated significantly enhanced CAR surface expression and functional quality, highlighting a clear link between avidity and therapeutic efficacy. This approach overcomes the limitations of conventional static in vitro assays by providing mechanistic, predictive insight into immune–tumour interactions. By enabling early, cost-efficient identification of high-performing CAR constructs, avidity-based profiling supports faster, safer, and more reliable development of next-generation cell-based immunotherapies while reducing reliance on animal models.
- [Assessment of cell engager-mediated T cell target engagement and function](https://avigen.bio/case-study-archive/etcembly/) - Discover how Avigen's avidity-based microfluidic platform resolved inconclusive cytotoxicity data for Etcembly's novel tri-specific and bi-specific T cell engagers, delivering mechanism-of-action insights and a clear, rank-ordered comparison of cell engager performance against melanoma targets that standard endpoint assays could not provide. Download the full case study to learn how paired avidity and functional data enables confident, de-risked cell engager selection for immunotherapy development.
- [Avidity assessment of cetuximab-mediated NK cell target engagement and function](https://avigen.bio/case-study-archive/nkio/) - Discover how Avigen's avidity-based microfluidic platform resolved inconsistent cytotoxicity data for NK:IO's Cetuximab-mediated NK cell programme, revealing CD16-dependent target engagement and donor-specific avidity differences that standard endpoint assays could not detect. Download the full case study to learn how paired avidity and functional data identified the optimal NK cell population for Cetuximab-driven ADCC, delivering mechanistic clarity that conventional cytotoxicity assays routinely miss.
- [Avidity-based detection, sorting and isolation of TCR T cells](https://avigen.bio/case-study-archive/tcr-t/) - Discover how Avigen's avidity-based platform accurately detects, sorts and isolates high-performing TCR T cells, revealing that avidity reliably predicts cytotoxic killing and T cell activation — delivering mechanistic insight that conventional cytotoxicity assays cannot provide. Download the full case study to learn how our approach enables faster, de-risked TCR T cell candidate selection for immunotherapy development.

## King Addons Templates

- [Discounted rates](https://avigen.bio/?king_addons_ext_pb=user-popup-discounted-rates)

## Categories

- [Press Release](https://avigen.bio/category/press-releases/)
- [Company News](https://avigen.bio/category/company-news/)

## Tags

- [Press release](https://avigen.bio/tag/press-release/)
- [Company News](https://avigen.bio/tag/company-news/)

## Project Categories

- [Audio](https://avigen.bio/neuros_project_category/audio/)
- [Development](https://avigen.bio/neuros_project_category/development/)
- [Modern](https://avigen.bio/neuros_project_category/modern/)

## Service Categories

- [Science](https://avigen.bio/neuros_services_category/science/)

## Case Study Tags

- [NK cells](https://avigen.bio/case-study-tag/nk-cells/)
- [ADCC](https://avigen.bio/case-study-tag/adcc/)
- [Solid tumour](https://avigen.bio/case-study-tag/solid-tumour/)
- [T cells](https://avigen.bio/case-study-tag/t-cells/)
- [Cell engager](https://avigen.bio/case-study-tag/cell-engager/)
- [Antibodies](https://avigen.bio/case-study-tag/antibodies/)
- [TCR T Cells](https://avigen.bio/case-study-tag/tcr-t-cells/)
- [CAR-iNKT](https://avigen.bio/case-study-tag/car-inkt/)
- [CAR](https://avigen.bio/case-study-tag/car/)